PERTH, AUSTRALIA and GREER, SC--(Marketwired - Oct 16, 2015) - Alexium International Group Limited (Alexium) (ASX: AJX) (AX: AJX) (OTCQX: AXXIY) is pleased to announce that based on the fire retardancy (FR) performance, environmental friendly formulation and value proposition of our Alexiflam™ chemistry, our major bedding client (for more details see press release on 14 September 2015) has expanded the use of our Alexiflam™ treatments to a second US national bedding brand under its corporate umbrella. Total annual revenue to Alexium from these two US national bedding brands is expected to be $5M USD ($6.8M AUD) pa, with revenue from this second brand to commence before the end of 2015. For customer marketing confidentiality reasons, the brand details will not be provided until products are in store. Dirk Van Hyning, President of Alexium, stated, "This second US national major brand is strong reinforcement of not just the value Alexium chemistries bring to the bedding market, but their ease of use, as this second program was developed proactively by our customer with limited involvement from Alexium staff. We anticipate our presence in this market segment will continue to grow from this solid foundation." About Alexium Alexium International Group Limited (ASX: AJX, AX:AJX OTC QX: AXXIY) holds proprietary patent applications for a process developed initially by the U.S. Department of Defense, which allows for the surface modification and attachment of nano-particles or multiple chemical functional groups to surfaces or substrates to provide functions such as fire retardancy, water proofing, oil proofing, and anti-microbial treatments. Applications under development include but are not limited to textiles, paints, and packaging, glass and building materials. Alexium's fire retardant chemical treatment are currently marketed for different fabric markets under the Ascalon™, Nycolon™, Nuvalon™, and Polytron™, Omnitron™, Bactron™ and Alexiflam™ trademarks. Contact Information: U.S. Contacts: Nick Clark Chief Executive Officer [email protected] U.S.: +1 864.991.6687 Bradi Dobson Marketing Specialist [email protected] U.S. R&D Center: 8 Distribution Court Greer, SC 29650 T: +1 864.416.1060 F: +1 864.752.6465 U.S. Corporate Office: 148 Milestone Way Greenville, SC 29615 T: +1 864.603.1165 F: +1 864.752.6465 Australia: Matt Wright Investor Relations [email protected] AUS: +61 451.896.420 ABN: 91 064 820 408 ASX: AJX
Alexiflam Chemistry Expands to Second Major Bedding Brand
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...